Panbela Therapeutics, Inc. (PBLA)
Company Description
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.
It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 6 |
CEO | Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. |
Contact Details
Address: 712 Vista Blvd #305 Waconia, Minnesota 55387 United States | |
Phone | (952) 479-1196 |
Website | panbela.com |
Stock Details
Ticker Symbol | PBLA |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001029125 |
CUSIP Number | 69833W107 |
ISIN Number | US69833W4042 |
Employer ID | 87-0543922 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | Chief Executive Officer, President and Director |
Susan Horvath | Vice President of Finance, Chief Financial Officer, Secretary and Treasurer |
Tammy Groene | Vice President of Operations |
Dr. Elizabeth Bruckheimer Ph.D. | Vice President and Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 10-K | Annual Report |
Mar 26, 2024 | 8-K | Current Report |
Mar 25, 2024 | PRE 14A | Other preliminary proxy statements |
Mar 7, 2024 | 8-K | Current Report |
Feb 15, 2024 | 8-K | Current Report |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | 8-K | Current Report |
Feb 1, 2024 | 8-K | Current Report |
Jan 30, 2024 | 424B4 | Prospectus |
Jan 29, 2024 | 8-K | Current Report |